Traduction de «new research » (Néerlandais → Français) :

TERMINOLOGIE

New Minto-virus
virus New Minto

epizootisch hemorrhagische ziekte, New Jersey-virus
virus Epizootic hemorrhagic disease, New Jersey

research | wetenschappelijk onderzoek
recherche | recherche

TRADUCTIONS EN CONTEXTE

FI – A new research on work stress and risk of cancer 05-03-2013
FI – A new research on work stress and risk of cancer 05/03/2013

Delivering innovation, growth and productivity The success of Novartis is driven by a commitment to three strategic priorities: (1) extending our lead in innovation through the research and development of differentiated new medicines, vaccines and diagnostics; (2) accelerating growth across all divisions by broadening our product portfolios with new launches and increasing our presence in new markets; and (3) improving profitability through productivity by streamlining and simplifying our processes.
Promouvoir l'innovation, la croissance et la productivité Le succès de Novartis est porté par son engagement envers trois priorités stratégiques: Augmenter notre avance dans l’innovation en recherchant et développant de nouveaux médicaments, vaccins et diagnostics différenciés, 2) accélérer notre croissance dans toutes les divisions en élargissant notre portefeuille par le lancement de nouveaux de produits et en accroissant notre présence dans de nouveaux marchés et 3) améliorer notre profitabilité par le biais de la productivité en rationalisant et en simplifiant nos processus.

In 2006 heeft de regering een nieuwe R&D-strategie opgesteld: Best Research for Best Health: a new national health research strategy.
En 2006, le gouvernement a adopté une nouvelle stratégie de R&D : Best Research for Best Health : a new national health research strategy.

Zoeken op de klassieke evidence based websites voor richtlijnen (Cochrane Library, US National Clearinghouse, NICE, SIGN, New Zealand Guidelines Group, National Health and Medical Research Council, Prodigy, CMA Infobase, GAC guidelines, Primary Care Clinical Practice Guidelines, AHRQ Agency for Healthcare Research and Quality, Clinical Evidence, National Library for Health (Guideline Finder), SumSearch) met de zoekterm “ ‘pneumonia’ and ‘nursing home’ “ levert geen resultaat op.
La recherche de directives sur les “evidence based websites” classiques (Cochrane Library, US National Clearinghouse, NICE, SIGN, New Zealand Guidelines Group, National Health and Medical Research Council, Prodigy, CMA Infobase, GAC guidelines, Primary Care Clinical Practice Guidelines, AHRQ Agency for Healthcare Research and Quality, Clinical Evidence, National Library for Health (Guideline Finder), SumSearch) avec les termes de recherche “ ‘pneumonia’ and ‘nursing home’ “ ne donne aucun résultat.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

“Pfizer’s commitments build on our ongoing efforts to fight neglected tropical diseases, which includes the work done through our support of the International Trachoma Initiative, by our colleagues who participate in our Global Health Fellows program, and through our participation in WIPO Re: Search -- a publicprivate consortium for sharing intellectual property and expertise with the global health research community to promote the development of new drugs, vaccines and diagnostics for the treatment of neglected tropical diseases, malaria and tuberculosis. “We are proud to be a part of this innovative effort to support a healthier world”.
“Pfizer’s commitments build on our ongoing efforts to fight neglected tropical diseases, which includes the work done through our support of the International Trachoma Initiative, by our colleagues who participate in our Global Health Fellows program, and through our participation in WIPO Re: Search -- a publicprivate consortium for sharing intellectual property and expertise with the global health research community to promote the development of new drugs, vaccines and diagnostics for the treatment of neglected tropical diseases, malaria and tuberculosis.

Consistent with this focused research strategy, new Phase II data demonstrates that ACZ885, currently marketed as Ilaris for the rare disease cryopyrin-associated periodic syndrome (CAPS), provided highly statistically significant risk reduction of acute flares in gout patients compared to the anti-inflammatory standard of care.
Cette approche stratégique est illustrée par ACZ885, un médicament actuellement commercialisé sous la marque Ilaris pour traiter le syndrome périodique associé à la cryopirine (CAPS), une maladie rare. De nouveaux résultats d’une étude de phase II ont montré que ce médicament induisait une réduction importante, hautement significative sur le plan statistique, du risque de crises aiguës de goutte par comparaison avec le traitement anti-inflammatoire standard.

Finally, the SCF pointed out that the possible interactions between caffeine, taurine and alcohol had not been correctly studied and that new research into the interactions between these ingredients was necessary in humans, especially in the event of physical effort accompanied by a considerable loss of water through sweating (SCF, 1999).
Enfin, le SCF a souligné que les interactions possibles entre ces constituants n’ont pas été bien étudiées et que les interactions entre la caféine, la taurine et l’alcool nécessitaient de nouvelles investigations chez l’homme, particulièrement lors d’un exercice physique associé à une intense perte d’eau par la sueur (SCF, 1999).

Dit verslag werd voorbereid door het Institute of Environmental Science and Research Limited, ESR (New Zealand Food Safety Authority, 2010b).
Celui-ci a été préparé par l’Institute of Environmental Science and Research Limited, ESR (New Zealand Food Safety Authority, 2010b).

If standards are too strict, then early phase research becomes virtually impossible and the discovery and development of new medicines will be severely impeded.
If standards are too strict, then early phase research becomes virtually impossible and the discovery and development of new medicines will be severely impeded.